2 weeks Ago By Defense World Staff
Prudential Financial Inc. decreased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 1.
6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,694 shares of the company’s stock after selling 630 shares during the quarter. Prudential Financial Inc.
owned about 0.08% of Amphastar Pharmaceuticals worth $1,437,000 as of its most recent filing with the Securities & Exchange Commission. Several other large investors have also added to or reduced their stakes in the stock.
LPL Financial LLC lifted its position in shares of Amphastar Pharmaceuticals by 8.0% in the 4th quarter. LPL Financial LLC now owns 20,366 shares of the company’s stock worth $756,000 after purchasing an additional 1,510 shares during the period.
Fox Run Management L.L.C.
purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth about $688,000. KLP Kapitalforvaltning AS bought a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at approximately $275,000. AXQ Capital LP purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth approximately $246,000.
Finally, Quantbot Technologies LP bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $945,000. Institutional investors own 65.09% of the company’s stock.
Insider Transactions at Amphastar PharmaceuticalsIn other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.
54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.
02. The trade was a 4.16 % decrease in their position.
The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 27.10% of the company’s stock.
Amphastar Pharmaceuticals Price PerformanceShares of NASDAQ:AMPH opened at $26.61 on Friday. The company has a debt-to-equity ratio of 0.
82, a current ratio of 3.43 and a quick ratio of 2.61.
The company has a market capitalization of $1.27 billion, a PE ratio of 8.87, a PEG ratio of 2.
19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc.
has a 1-year low of $25.89 and a 1-year high of $53.96.
The business has a fifty day moving average price of $30.24 and a 200-day moving average price of $39.25.
Wall Street Analyst Weigh InSeparately, Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st.
Check Out Our Latest Report on AMPHAmphastar Pharmaceuticals Company Profile (Free Report)Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.Featured StoriesFive stocks we like better than Amphastar PharmaceuticalsShort Selling – The Pros and Cons Conagra Stock Could Thrive as Tariffs Hit Other SectorsWhat is an Earnings Surprise? Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsStock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be ClosedSpotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?.
